Revenue segments as reported by the company.

Pharmaceutical

Animal Health

Other Revenues

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Selling, general and administrative

Research and development

Restructuring costs

Other (income) expense, net

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Merck

Merck & Co., Inc. engages in the provision of health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products. It operates through the following segments: Pharmaceutical, Animal Health, and Other. The Pharmaceutical segment includes human health pharmaceutical and vaccine products. The Animal Health segment discovers, develops, manufactures, and markets animal health products, such as pharmaceutical and vaccine products, for the prevention, treatment and control of disease in livestock and companion animal species. The Other segment consists of sales for the non-reportable segments of healthcare services. The company was founded in 1891 and is headquartered in Kenilworth, NJ.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Merck reports robust Q4 earnings, eyes growth through innovation

Merck's Q4 2022 performance reflects strong revenue growth and strategic advancements across key therapeutic areas, positioning the company for future success.
While facing challenges such as patent estate concerns and competitive pressures, Merck's focus on innovation and partnerships presents opportunities for sustained growth.
Analyst inquiries and executive responses during the earnings call highlight the company's commitment to transparency, patient outcomes, and shareholder value.

Merck reports robust Q1 earnings, eyes growth in oncology and vaccines

Merck's Q1 performance reflects strong revenue growth driven by oncology and vaccines, with a raised full-year guidance and focus on pipeline advancements.
The company's strategic strengths lie in its focus on compelling science, value alignment in business decisions, and commitment to innovation.
Challenges include potential impacts of EU legislation, post-KEYTRUDA LOE growth strategies, and navigating regulatory complexities for new treatments.
Opportunities in expansion in China, revenue diversification, innovative combination therapies, and protective treatment strategies position Merck for future growth.

Merck reports robust Q2 earnings, focuses on growth opportunities

Merck's Q2 performance showcased strong earnings driven by Oncology and Vaccines growth
Despite challenges like regulatory concerns and price pressures, the company remains focused on innovation
Opportunities lie in expanding KEYTRUDA's reach in cancer indications and advancing in immunology
Overall, Merck's strategic acquisitions and commitment to growth position it well for the future

Merck reports robust Q3 earnings, eyes growth in precision medicine

Merck's Q3 2023 Earnings Call highlighted strong revenue growth, pipeline advancements, and increased full-year revenue guidance. The company's strategic focus on key therapeutic areas and precision medicine approaches positions it for continued success and innovation.

Merck reports robust Q4 earnings, eyes growth through strategic investments

Merck's strong Q4 performance was driven by KEYTRUDA and Vaccines, with positive revenue guidance for 2024. The company remains focused on R&D advancements, strategic investments, and shareholder value. Challenges include managing expenses and maximizing market opportunities.

Merck reports robust Q1 earnings, eyes growth in innovative treatments

Merck's Q1 performance reflects strong revenue growth, operational efficiency, and a positive outlook for future earnings.
The company's focus on innovation, strategic investments, and commitment to patient access position it well for long-term success.
Challenges in pipeline differentiation and market competition require continued strategic planning and differentiation strategies.
Opportunities in new treatment areas, market expansion, and upcoming events offer avenues for sustained growth and market leadership.

Merck reports robust Q2 earnings, eyes future drug launches

Merck's Q2 earnings call highlighted strong financial performance, innovative product launches, and confidence in future growth. The company addressed analyst inquiries, emphasizing long-term pipeline growth and short-term financial guidance while expressing gratitude for investor support.

Merck reports solid Q3 earnings, eyes growth through diversification

Merck's Q3 2024 performance reflects revenue growth driven by key products and clinical advancements, despite regional sales variations and inventory challenges.
The company's strengths in diversification, clinical progress, and strategic investments position it well for future growth and competitive edge in the market.
While facing challenges in specific product sales and clinical trials, Merck has opportunities to capitalize on its strengths, expand offerings, and drive sustained growth.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Merck & Co., Inc. is a health care company, which engages in the provision of health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products. It operates through the following segments: Pharmaceutical, Animal Health, and Other. The Pharmaceutical segment includes human health pharmaceutical and vaccine products. The Animal Health segment discovers, develops, manufactures, and markets animal health products, such as pharmaceutical and vaccine products, for the prevention, treatment and control of disease in livestock, and companion animal species. The Other segment consists of sales for the non-reportable segments of healthcare services. The company was founded in 1891 and is headquartered in Rahway, NJ.

DARMSTADT, Germany--(BUSINESS WIRE)--Merck, a leading science and technology company, today provided an overview of its innovative pipeline with a focus on five mid- to late-stage assets with first-in-class and/or best-in-class potential at its R&D Update Call. “At Merck we are working to translate our extensive expertise and deep knowledge in key tumors and neurological and immunological diseases with a goal to change treatment paradigms and improve patient outcomes,” said Danny Bar-Zohar,

Merck Highlights Novel Mechanisms with the Potential to Transform Standards of Care in Several Cancers, MS, and Lupus

KENILWORTH, N.J.--(BUSINESS WIRE)---- $MRK #MRK--Merck Completes Tender Offer to Acquire Acceleron Pharma Inc.

Merck Completes Tender Offer to Acquire Acceleron Pharma Inc.

EMA's human medicines committee (CHMP) advised that the COVID-19 pill from Merck & Co Inc (NYSE: MRK) should be given within five days of first symptoms to treat adults who do not need oxygen support and are at risk of their disease worsening. The European Medicines Agency (EMA) said the pill, developed along with Ridgeback Biotherapeutics, should be taken twice a day for five days.

EU Backs Merck's COVID-19 Pill For Adults At Risk Of Severe Illness

The regulator said earlier that it is expected to finalize its authorization of the drug by the end of this year.

EU Drug Regulator Backs Emergency Use Of Merck's Covid Antiviral Pill

Merck's (MRK) anti-PD-1 therapy Keytruda gets FDA nod as an adjuvant treatment for patients with renal cell carcinoma at intermediate-high or high risk of recurrence, following nephrectomy, or following nephrectomy and resection of metastatic lesions.

Merck's (MRK) Keytruda Gets Approval for Certain RCC Patients

Pfizer

It looks to be more effective and will sell at a comparable price.

Will Pfizer's COVID Pill Crush the Hopes of Merck Investors?

Merck & Co Inc (NYSE: MRK) announced an update regarding the Phase 2 IMAGINE-DR trial (MK-8507-13), evaluating the combination of MK-8507 and islatravir (ISL) as a once-weekly oral treatment for HIV-1 infection.  Decreases in total lymphocyte and CD4+ T-cell counts were observed in study participants randomized to receive ISL+MK-8507.

Merck Pauses Development Of MK-8507 In HIV Infection

KENILWORTH, N.J.--(BUSINESS WIRE)---- $MRK #MERCK--Merck Update on Phase 2 Clinical Trial of Once-Weekly Investigational Combination of MK-8507 and Islatravir for Treatment of People Living with HIV-1

Merck Provides Update on Phase 2 Clinical Trial of Once-Weekly Investigational Combination of MK-8507 and Islatravir for the Treatment of People Living with HIV-1

The FDA has approved Merck & Co Inc's (NYSE: MRK) Keytruda, an anti-PD-1 therapy, for the adjuvant treatment of renal cell carcinoma (RCC). The news comes almost half a year after Merck took the stage at ASCO to report Phase 3 data showing Keytruda cut the risk of cancer relapse or death by 32% compared to placebo, hitting the primary endpoint of disease-free survival.

Merck's Keytruda Scores First Approval In Adjuvant Kidney Cancer Setting

AbbVie

Bristol-Myers

Warren Buffett's Berkshire Hathaway Inc (NYSE: BRK-A) cleared its stake in Merck & Co Inc (NYSE: MRK) in Q3, right on the eve of a significant stock price boost thanks to the Phase 3 success of its Ridgeback Biotherapeutics-partnered COVID-19 pill molnupiravir. The molnupiravir data sent Merck's share price from about $75 apiece the previous day to as high as about $84.

Berkshire Exited Merck Before COVID Pill Boost; Trimmed Holdings In AbbVie, Bristol Myers In Q3

KENILWORTH, N.J.--(BUSINESS WIRE)---- $MRK #MERCK--FDA Approves Merck's KEYTRUDA® (pembrolizumab) as Adjuvant Therapy for Certain Patients With Renal Cell Carcinoma (RCC) Following Surgery

FDA Approves Merck's KEYTRUDA® (pembrolizumab) as Adjuvant Therapy for Certain Patients With Renal Cell Carcinoma (RCC) Following Surgery

Goldman Sachs

iShares Core S&P 500 ETF

SPDR S&P 500 ETF Trust

Vanguard S&P 500 ETF

Goldman Sachs (GS) this week said that it expects the S&P 500 to rise 9% to 5,100 by the end of 2022, as quoted on a Yahoo Finance article.

Goldman Fans Can Reap Returns From S&P 500 ETFs in 2022

Antiviral pills that treat Covid are on the way to approval. Here's what you need to know about molnupiravir from Merck and Paxlovid from Pfizer, two promising medications.

These 2 Covid pills could be available soon — and they might help end the pandemic. Here's how

KENILWORTH, N.J.--(BUSINESS WIRE)---- $MRK #MRK--Merck Announces Expiration of Hart-Scott-Rodino Act Waiting Period and Extension of Tender Offer to Acquire Acceleron Pharma Inc.

Merck Announces Expiration of Hart-Scott-Rodino Act Waiting Period and Extension of Tender Offer to Acquire Acceleron Pharma Inc.

Merck MRK, +0.50% and partner privately held Ridgeback Biotherapeutics will present data from a Phase 3 trial of their COVID-19 antiviral molnupiravir at the American Society of Tropical Medicine and Hygiene (ASTMH) 2021 Annual Meeting taking place virtually starting later Wednesday. "Poster data will be available on Wednesday, Nov. 17 at 9 a.m.

Merck and Ridgeback Biotherapeutics to present Phase 3 data from COVID antiviral at ASTMH meeting at 9. a.m.

KENILWORTH, N.J. & MIAMI--(BUSINESS WIRE)---- $MRK #MERCK--Merck and Ridgeback to Present Phase 3 Data for Molnupiravir, an Investigational Oral COVID-19 Antiviral Medicine, at ASTMH 2021 Annual Meeting

Merck and Ridgeback to Present Phase 3 Data for Molnupiravir, an Investigational Oral COVID-19 Antiviral Medicine, at American Society of Tropical Medicine and Hygiene (ASTMH) 2021 Annual Meeting

Chevron

Floor & Decor Holdings

Marsh & McLennan

Organon & Co

Royalty Pharma

Warren Buffett (Trades, Portfolio)'s Berkshire Hathaway ( BRK.A , Financial) ( BRK.B , Financial) published its third-quarter 13F filing earlier this week, reporting U.S. equity position changes during the three months to the end of September.

Buffett Continues to Sell Stock as Turnover Increases

Agilent Technologies

Motorola Solutions

NIKE

After years of a low interest rate environment, many investors have turned to equities not only for the growth potential but also for solid and dependable dividends, which help to provide an income stream.

4 Top Analyst Stock Picks With Dividend Hikes Expected This Week

Pfizer has been beating MRK stock in 2021, but that relative performance may reverse next year, with new drugs and acquisitions ahead. The post Merck Is a Dividend Play Ready to Get Back in Gear appeared first on InvestorPlace.

Merck Is a Dividend Play Ready to Get Back in Gear

Charter Communications

Liberty Global Ltd

Liberty Media Corp-Liberty SiriusXM

Mastercard

U.S. Bancorp

Visa

Berkshire Hathaway CEO Warren Buffett kept up his bearish streak in Q3 2021, but he did add a pair of positions from two of his favored industries.

10 Stocks Warren Buffett Is Selling (And 4 He's Buying)

Imugene Limited (ASX:IMU, OTC:IUGNF) has advanced another treatment in its development pipeline through a clinical trial supply agreement with Merck KGaA, Darmstadt, Germany, and Pfizer Inc (NYSE:PFE) to evaluate the safety and efficacy of Imugene's HER-Vaxx, in combination with avelumab, in patients with HER-2 positive gastric cancer. HER-Vaxx is Imugene's B-cell activating immunotherapy, which will be assessed in conjunction with avelumab, an immune checkpoint inhibitor targeting PD-L1 which is marketed as BAVENCIO® and co-developed and commercialised by Merck KGaA and Pfizer.

Imugene secures clinical trial supply agreement with Merck KGaA and Pfizer for HER-Vaxx gastric cancer trial

Warren Buffett's Berkshire Hathaway Inc said on Monday it eliminated its investment in Merck & Co and reduced its stakes in Abbvie Inc and Bristol-Myers Squibb Co, as it pared its overall stock market investments.

Buffett's Berkshire cuts stakes in U.S. drugmakers, invests in drug royalty company

AmerisourceBergen

Automatic Data Processing

American Equity Investment Life

Aflac

Assurant

Atmos Energy

Becton, Dickinson and Co.

Emerson Electric

Evergy Inc

Griffon

Huntington Ingalls Industries

Hormel Foods

Hawthorn Bancshares

Lancaster Colony

Matthews International

Mercury General

MDU Resources Group

McCormick

Nelnet

Royal Gold

Roper Technologies

South Jersey Industries

Snap-on

Spire

York Water

Investors saw a few very good dividend increases in the first half of November, with ADP, Snap-on, and Roper Technologies announcing double-digit boosts, and a massive 29% boost from HP. The second half of November will bring double-digit boosts from a few more companies including Nike, Motorola Solutions, Aflac, and Agilent Technologies.

Second Half Of November Brings Dividend Increases From Merck, Nike And 12 Others

Better Buy: Bristol Myers Squibb vs. Merck

Alibaba

Johnson & Johnson

Royal Dutch Shell's pension fund exited an investment in Alibaba, and slashed positions in Pfizer, Johnson & Johnson, and Merck in the third quarter.

Shell's Pension Dropped Alibaba and Sold Big Pharma Stocks

News for Merck Stock (MRK)